Synageva, Mitsubishi extend deal on protein drugs for rare disease

04/4/2012 | Genetic Engineering & Biotechnology News

Mitsubishi Tanabe Pharma and Synageva BioPharma will jointly develop a second therapeutic protein for an orphan disease using the latter's protein expression platform as part of their expanded rare-disease deal. Synageva will receive $9 million in upfront fees and reimbursement for development costs, plus potential milestone payments and sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Commercial Health Insurance Strategist__Job #52-14
American Academy of Family Physicians
Leawood, KS
Manager of Payer Relations
Pharmacy Quality Solutions, Inc.
Raleigh/Durham, NC
Director of Product Planning Development; Market Planning, Innovation
Blue Cross Blue Shield of Massachusetts
Quincy , MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ